Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446066 | 0.80 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL2265394 | 0.79 | KDM4E (0.35) | — | |
| SCHEMBL6524170 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL3570600 | 0.76 | KDM4E (0.42) | ALDH1A1 | |
| SCHEMBL1192950 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL3558292 | 0.74 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL934315 | 0.74 | KDM4E (0.50) | ALDH1A1 | |
| SCHEMBL940204 | 0.73 | KMT2A (0.42) | ALDH1A1 | |
| SCHEMBL24307969 | 0.70 | ADRB2 (0.39) | — | |
| SCHEMBL23569789 | 0.69 | POLB (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711473-B1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1711473-A1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-0777667-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | Dr. Karl Thomae GmbH (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005194-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | DR. KARL THOMAE GMBH (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | ALDH1A1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.